Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-12-17 (baystreet.ca)
.ca - Why are Biogen, Pfizer, and GSK Trading at a Discount?
Last week, Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth catalysts. Demand for Biogen’s Alzheimer’s drug, Leqembi, is still slow. Although analysts at Needham are expecting ...
Read more
2024-05-26 (fiercepharma.com)
Biogen, Samsung Bioepis launch first US biosimilar, a copycat of Roche's Lucentis, at 40% discount
Ten years after the formation of biosimilar-focused joint venture Samsung Bioepis, Biogen is finally launching its first U.S. biosimilar. | Ten years after the formation of the biosimilar-focused joint venture Samsung Bioepis, Biogen is finally launching its first U.S. biosimilar.
Read more
2024-02-23 (ariva.de)
Minimal price discount for the Biogen share (€205.4700)
Biogen shares are currently unremarkable on the US stock market. The paper is currently trading at $222.34.
Read more
2023-03-28 (morningstar.it)
2 pharmaceutical stocks trading at a discount
GSK and Biogen operate in a defensive segment such as biopharma, have a high Moat, can count on good growth prospects and have attractive market valuations.
Read more
2022-02-07 (globenewswire.com)
Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
Biosimilars have the potential to broaden patient access to effective and more affordable treatments and generate healthcare savings...
Read more
2021-08-20 (healthjournalism.org)
Explaining Biogen’s controversial ‘MCI’ advertising to your audience | Association of Health Care Journalists
New marketing campaigns about forgetfulness and distraction could lead people to seek the costly Aduhelm drug for Alzheimer’s disease even…
Read more
2019-11-21 (healthtalk.no)
Decision-making forum considers new price for the MS drug Tysabri and treatment of severe hair loss
The decision-making forum must assess whether the reduced supply of the MS drug Tysabri is good enough for introduction. They will also consider treatment of severe hair loss with the medicine Litfulo.
Read more
2018-08-13 (reuters.com)
Biogen's pricey muscle drug Spinraza too costly for Britain
Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker.
Read more
2017-04-12 (barrons.com)
Celgene, Biogen to Gain From Higher Prices
Heading into earnings, Biogen, Alexion Pharmaceuticals and Gilead Sciences could be in focus.
Read more
(morningstar.com)
Biogen prices new ALS treatment at $14,230 per vial
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished
Read more